share_log

Raymond James Upgrades ARS Pharmaceuticals to Strong Buy, Raises Price Target to $22

Benzinga ·  Aug 13 17:35  · Ratings

Raymond James analyst Ryan Deschner upgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Outperform to Strong Buy and raises the price target from $18 to $22.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment